Exemestane
9 NDCs across 9 manufacturers|8 Generic,1 Brand
Exemestane is used to treat breast neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 21, 1999, and the first generic was approved Apr 1, 2011. FDA's Orange Book lists 8 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $33 million on Exemestane across 213,000 claims for 55,000 beneficiaries.
Exemestane is available as 9 NDCs from 9 manufacturers (8 generic, 1 brand), with NADAC prices from $0.75 to $38.98 per EA — the most expensive product costs about 52× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
9
8G / 1B
Manufacturers
9
competing in market
Price Spread
$0.75 – $38.98
per EA
7d Activity
avg +4.2% WoW · of 9 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Pharmacia & Upjohn Company LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Aromatase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
9 manufacturers producing EXEMESTANE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
AROMASIN 25 MG TABLET | $38.9792 per EA | — |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
EXEMESTANE 25 MG TABLET | $0.7478 per EA | +4.19% |
Frequently Asked Questions
What is Exemestane used to treat?
Exemestane is used to treat breast neoplasms, per the National Library of Medicine's MED-RT classification.
When did Exemestane become available as a generic?
FDA approved the first generic Exemestane (ANDA) on Apr 1, 2011. The Orange Book currently lists 8 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Exemestane?
In 2024, Medicare Part D spent $33 million on Exemestane across 213,000 claims for 55,000 beneficiaries.
How many Exemestane products are on the market?
The Exemestane drug market contains 9 NDCs from 9 manufacturers — 8 generic and 1 brand product.
What is the price range for Exemestane?
NADAC reference prices for Exemestane range from $0.7478 to $38.9792 per EA — the most expensive product costs about 52× the cheapest.
Is generic Exemestane cheaper than brand?
The average generic NADAC for Exemestane is $0.7478 per EA, versus $38.9792 for brand-labeled products — brand versions average about 52× the generic price.
Which manufacturers make Exemestane?
9 manufacturers list Exemestane in NADAC. Ranked by number of NDCs, the largest are Pharmacia & Upjohn Company LLC (1), Breckenridge Pharmaceutical Inc. (1), Aurobindo Pharma Limited (1), Mylan Pharmaceuticals Inc. (1), Upsher-Smith Laboratories LLC (1).
How has the price of Exemestane changed recently?
Over the past 7 days, 8 Exemestane NDCs rose and 0 fell, with a market-wide average change of +4.2%.